Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Standard of care.
- Who it may be relevant to
- Registry conditions: Multiple Myeloma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
Overview
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Interventions
- Diagnostic test Standard of care
Participants will not receive any intervention in this study. Participants will receive standard of care therapy
Primary outcome measures
- To validate the sensitivity of Telo Genomics assay (measurement tool) to detect MRD (measurement expressed in the number of plasma cells per 100000 cells) and establish the clinical utility of TELO - DMRD for MRD enumeration [Time frame: Approximately 5 years]
- To assess the utility of TeloView® technology genomic profiling (measurement tool) to stratify post-transplant MM patients into relapse risk groups (dichotomous measure of high or low) by analyzing the residual MRD plasma cells [Time frame: Approximately 5 years]
Eligibility criteria
Inclusion criteria
- Confirmed MM diagnosis
- Transplant eligible patients in a first remission
- Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
- Availability of deidentified patient's demographic and clinical follow up data
- Receiving standard of care treatment
- Able to provide informed consent
Exclusion criteria
- Failure to meet inclusion criteria
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Canada · 1 center
- Jewish General Hospital — Montreal
Identifiers
NCT: NCT05530096 · Telo Genomics Study